Aspirin News and Research

RSS

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.

AAN publishes updated practice advisory on closure of common heart defect after stroke

New guidance from the American Academy of Neurology concludes that closure of a common heart defect called a patent foramen ovale may be recommended for some people who have had a stroke.

29 Apr 2020

Scientists discover anti-cancer compound in the humble willow

More than a century after giving the world aspirin, another potential drug has been found in the stem and leaves of willows – this time with anti-cancer properties.

17 Apr 2020

Aspirin associated with reduction in risk of several digestive tract cancers

Aspirin is associated with a reduction in the risk of developing several cancers of the digestive tract, including some that are almost invariably fatal, such as pancreatic and liver cancers.

15 Apr 2020

Newer therapies may benefit patients with type 2 diabetes and coronary artery disease

Type 2 diabetes affects treatment options for patients who have both coronary artery disease and T2D, according to a new American Heart Association Scientific Statement, published today in the Association's flagship journal Circulation.

13 Apr 2020

People with type 2 diabetes and heart disease may benefit from newer therapies

Type 2 diabetes (T2D) may affect treatment options for patients who have both coronary artery disease (CAD) and T2D.

13 Apr 2020

Excess cardiac myosin worsens damage to heart tissue during a heart attack

A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

2 Apr 2020

Her genetic test revealed a microscopic problem — and a jumbo price tag

Michelle Kuppersmith, 32, feels great, works full time and exercises three to four times a week. So she was surprised when a routine blood test found that her body was making too many platelets, which help control bleeding.

31 Mar 2020

Ticagrelor therapy, without aspirin, can benefit patients with acute coronary syndrome

Patients with acute coronary syndrome (ACS) who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for nine months had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

31 Mar 2020

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

31 Mar 2020

Higher serum EPA levels from prescription fish oil associated with lower cardiovascular events

Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood—and not a decrease in triglyceride levels as originally thought—appear to explain the striking reductions in cardiovascular events and deaths seen among people taking 4 grams daily of the prescription fish oil, icosapent ethyl, according to findings from a REDUCE-IT substudy presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

30 Mar 2020

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

An international clinical trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its stated goal for cutting in half the incidence of serious adverse cardiovascular events, such as heart attack and stroke, in the year following the procedure.

30 Mar 2020

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.

From AstraZeneca 30 Mar 2020

Taking ticagrelor alone better for patients with complex heart disease

Patients with complex heart disease who stopped taking aspirin three months after the insertion of one or more coronary stents and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor over the same period.

30 Mar 2020

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

30 Mar 2020

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Study contradicts theory that daily aspirin prevents dementia symptoms

Scientists have disproven the theory that taking a low dose of daily aspirin reduces cognitive symptoms of dementia.

25 Mar 2020

Listening to music for 30 minutes a day provides benefits after heart attack

Listening to music can be enjoyable, but is it also good for your heart? Patients who suffered episodes of chest pain soon after a heart attack, known as early post-infarction angina, had significantly lower levels of anxiety and pain if they listened to music for 30 minutes a day, according to a study presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

18 Mar 2020

Aspirin News and Research

AAN publishes updated practice advisory on closure of common heart defect after stroke

Scientists discover anti-cancer compound in the humble willow

Aspirin associated with reduction in risk of several digestive tract cancers

Newer therapies may benefit patients with type 2 diabetes and coronary artery disease

People with type 2 diabetes and heart disease may benefit from newer therapies

Excess cardiac myosin worsens damage to heart tissue during a heart attack

Her genetic test revealed a microscopic problem — and a jumbo price tag

Ticagrelor therapy, without aspirin, can benefit patients with acute coronary syndrome

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Higher serum EPA levels from prescription fish oil associated with lower cardiovascular events

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Taking ticagrelor alone better for patients with complex heart disease

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

Study contradicts theory that daily aspirin prevents dementia symptoms

Listening to music for 30 minutes a day provides benefits after heart attack

Low-dose aspirin linked to lower risk of hepatocellular carcinoma and liver-related mortality

Heart Association puts halt to Bayer’s giant displays of baby aspirin

Heart attack patients who follow more medical advice have greater long-term survival

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News